ClinicalTrials.gg
RecruitingNCT06116942Updated Nov 9, 2023

Magnetic Brain Stimulation and Computer-based Motor Training for Rehabilitation After Stroke

An interventional study of Active rTMS and Sham rTMS in Chronic Stroke, sponsored by Max Planck Institute for Human Cognitive and Brain Sciences. Recruiting at 1 site in Germany. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-09.

Sponsored by Max Planck Institute for Human Cognitive and Brain Sciences · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 356 studies in Stroke with a site in Germany — 51 open to participants now, 66 under way, 8 of them phase 3. Stroke · Germany.

Planned enrollment
194th of 222
24 · median 200
Started
2023
with 11 others
No phase
104 of 356
18 open now
Primary completion
2026-09
later than 24 of 65 live
Registered
318th of 356
by date

Among the 356 studies in Stroke with a site in Germany, this one is the 194th largest by planned enrollment of the 222 interventional ones that give a count, is one of 12 that started in 2023, is one of 104 with no phase, reaches primary completion later than 24 of the 65 other live ones, and was the 318th registered.

Stroke

8,281 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

51 of the 356 studies in Stroke with a site in Germany are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 356 studies in Stroke with a site in Germany, or all of them as a file.
02

Study summary

The goal of the present clinical trial is to explore whether an innovative technology-based approach can help individuals who have had a stroke and can no longer move their hands with ease. Our approach consists of a combination of two technologies: Transcranial Magnetic Stimulation (TMS) and a Brain-Computer Interface (BCI). The former entails the application of magnetic fields over the head to stimulate the brain preparing it for a better ability to produce movement. The latter consists of measuring brain activity to personalize a type of computer-based training that is designed to increase communication between the brain and the muscles.

Read the detailed description

Aims of the study:

  1. to provide preliminary evidence of the effect of rTMS (repetitive Transcranial Magnetic Stimulation) on brain-computer interface (BCI)-mediated plasticity on individuals with hemiparesis after stroke
  2. Measure adherence and withdrawal rates of the present protocol for informing a future large-scale randomized controlled trial

The active stimulation (rTMS) consists of an intermittent theta burst (iTBS) protocol whereas the placebo condition encompasses rTMS stimulation delivered with a Sham coil (Sham).

Procedures:

The study will entail 25 sessions. The study is composed of six different types of sessions in a crossover design:

  1. Screening session (day 1): Includes the informed consent form signature, enrollment and BCI calibration
  2. Before-treatment and after-treatment sessions (day 2, 13, 14 and 25) include the recording of EEG and MRI data, as well as the application of tests and questionnaires for evaluation of motor function
  3. Daily visit with blood draw sessions (days 3, 12, 15 and 24): consist of the delivery of active or sham rTMS followed by BCI training preceded and followed by a blood draw.
  4. Daily visit sessions without a blood draw (days 4 to 11 and 16 to 23): consist of the delivery of active or sham rTMS followed by BCI training.

After a screening session (day 1), the clinical study begins. The period I of the study begins with a before-treatment session (day 2). Then, the intervention (rTMS or sham followed by BCI training) is delivered during 10 daily visits over a 2-week period excluding weekends (days 3 to 12). Within the daily visits, there are 2 daily visits with blood draws (days 3 and 12) and the rest do not include any blood draws (days 4 to 11). Then, an after-treatment session takes place (day 13).

After period I, a washout period of 4 weeks takes place. No measurements or training are required during this time. In Period II of the study, the session flow is repeated except for the screening session. Therefore, period II includes a before-treatment session (day 14), 10 daily visits (days 15 to 24), with 2 daily visits that include blood draws (days 15 and 24), and an after-treatment session (day 25).

Research questions:

  1. Does rTMS promote better motor recovery after BCI training in comparison to sham?
  2. Can rTMS propitiate stronger effects on neural physiology after BCI training in comparison with sham?
  3. Is there an association between behavioral and physiological changes after the proposed intervention?
  4. What is the adherence and withdrawal rate and reason for withdrawal of the proposed study design and procedures?
  5. Is there an association between brain structures associated with motor function at baseline and the changes observed after rTMS?
  6. Can applying rTMS have a better effect on self-perceived motor performance in daily activities in comparison to Sham?
  7. Are serum molecular markers of plasticity and neural turnover modulated by rTMS?

Hypotheses:

  1. A higher increase in motor performance will be observed after the rTMS-BCI in comparison with sham-BCI. The motor performance will be assessed as Fugl-Meyer Assessment for upper extremity score as the primary outcome measure; and as the Jebsen Taylor hand function test and BCI accuracy as the secondary outcome measures
  2. Higher physiological changes will be observed after rTMS-BCI in comparison with sham-BCI. The electrophysiological changes will be assessed as Motor evoked potentials, as primary outcome measured; and as motor-related cortical potentials, Event-Related Desynchronization and functionalMagnetic Resonance Imaging changes as secondary outcome measures
  3. Behavioral and physiological changes will be associated
  4. Changes in structural MRI will be associated with behavioral outcome measures after rTMS-BCI and sham-BCI. Structural MRI will be assessed as Fractional Anisotropy changes, as a primary outcome measure; and voxel-based morphometry as a secondary outcome measure
  5. Individuals will have a higher perceived improvement in activities of daily living, measured as higher scores in the Upper extremity motor activity log (UE-MAL) and the first and last items of the Stroke impact scale (SIS) questionnaire after rTMS-BCI in comparison with sham-BCI
  6. The increase in Brain-Derived Neurotrophic Factor (BDNF) will be higher after rTMS-BCI in comparison with after sham-BCI and an association between BDNF levels and behavioral markers of motor recovery will exist

As an exploratory analysis, the investigators will inspect preliminary evidence of the effects of the stimulation by verifying changes in serological markers of neuronal plasticity and turnover.

03

Conditions studied

  • Chronic Stroke

Browse trials for

Keywords

  • Transcranial Magnetic Stimulation
  • Intermittent Theta Burst Stimulation
  • Brain-Computer Interface
  • Rehabilitation
  • EEG
  • MRI
  • Molecular changes
  • Brain plasticity
  • Stroke
  • Hemiparesis
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of a subcortical stroke at least 6 months before the initiation of the trial and confirmed with magnetic resonance imaging (MRI) or computed tomography
  2. Present moderate to severe hemiparesis in an upper limb
  3. Language comprehension as well as visual and auditory perception sufficient to engage in Brain Computer Interface training
  4. Age from 20 to 80 years old
  5. Clear consciousness and stable vital signs
  6. Eligible for MRI, EEG, BCI and TMS methods

Exclusion criteria

Exclusion Criteria:

  1. Drug abuse or recent changes in medications that may alter the central nervous system when the measurements begin or during the measurements (e.g., benzodiazepines, serotoninergic and dopaminergic agents)
  2. History of seizure
  3. Bone, joint and muscle diseases
  4. Peripheral neuropathy or other neurological or psychiatric diseases (including, tinnitus, migraine, or mood disorders with the exception of minimal, mild, and moderate depression, reflected as a Beck depression scale score lower than 29).
  5. Strong cognitive deficits (including speech, attention, hearing, vision, sensation or intelligence deficits) reflected as a (MoCA) score lower or equal to 24
  6. Lesions in the upper extremities
  7. Bone, joint and muscle diseases
  8. Severe spasticity (higher than 3) or pain in the upper limb and affecting wrist extension
  9. of undergoing TMS examinations: history of seizures, history of epilepsy, unclear unconsciousness, migraines or metals on the head
  10. Contraindications for MRI: metals in the body, metallic prosthetics or claustrophobia
  11. Participation in other interventional trials using BCI or rTMS within less than 6 months ago
  12. Participation in another interventional clinical trial
  13. Suspected lack of compliance
  14. Pregnant or nursing women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Active stimulation - Placebo stimulation

    Participants will undergo a 2 intervention periods. The first intervention period will consist of a 2-week course of rTMS followed by BCI-mediated training. This intervention will be succeeded by a 4-week washout period to mitigate any carry-over effects. The second intervention period will entail 2 weeks of sham rTMS followed by BCI-mediated training.

    Device: Active rTMS · Device: Sham rTMS

  • Experimental
    Placebo stimulation - Active stimulation

    Participants will undergo the same interventions as the first arm but delivered in inverse order. The first intervention period will consist of 2 weeks of sham rTMS followed by BCI-mediated training. The second intervention period will entail 2 weeks of rTMS prior to BCI-mediated training and will start after a 4-weeks washout period.

    Device: Active rTMS · Device: Sham rTMS

Interventions

  • DeviceActive rTMS

    The Transcranial Magnetic Stimulation will consist of placing a figure-of-eight shape coil of wire over the head of the participants. Then, a brief electric current will pass through the coil, inducing a magnetic field capable of stimulating neurons located beneath the coil. For the active coil, the maximal stimulation intensity is reached beneath the center of the coil. In the present study, the intermittent theta-burst protocol will be implemented. This protocol is expected to modulate the excitability of the brain, priming it for a stronger activation of the motor-related brain areas engaged during brain-computer interface-based training. The structural MRI of each participant will be used to guide neuronavigation towards ipsilesional motor areas.

    Also known as: Intermittent Theta Burst Stimulation, Repetitive Transcranial Magnetic Stimulation, iTBS

  • DeviceSham rTMS

    To implement a placebo stimulation, a sham coil will be used to deliver the same stimulation protocol. The sham coil is identical in dimensions and weight to the active coil but produces a diminished magnetic field. For the sham coil, the stimulation intensity is minimal beneath the center of the coil, the same area with the highest intensity during stimulation with an active coil. The structural MRI scan of each participant will be used to guide neuronavigation towards the same area where the active stimulation was applied.

    Also known as: Placebo Intermittent Theta Burst Stimulation, Placebo Repetitive Transcranial Magnetic Stimulation, Sham iTBS

06

What researchers measure

Primary outcomes

  1. Motor-evoked potential (MEP) parameters

    An MEP is the electromyography response to a single TMS pulse delivered over the motor cortex, over the representation of multiple muscles. MEP changes will be evaluated with a mixed effects model. mixed-effects model. The model will consider the Patient, Period, Treatment (stimulation type) and Session number. The Period\*Treatment interaction will be verified to detect carry-over effects. The investigators expect to observe a main effect of Treatment and Session number.

    Time frame: Measured two times per day, at the days: 3-12 and 15-24. The first measurement is performed immediately before the rTMS-BCI intervention and the second immediately after the rTMS-BCI intervention.

  2. Fugl-Meyer upper extremity assessment of sensorimotor function

    Quantitative evaluation of motor, balance, sensation and joint functions. The sums of values recorded before and after the stimulation periods will be fed into an unpaired sample t-test to evaluate carryover effects whereas the differences observed between recordings before and after the stimulation will be fed into an unpaired sample t-test for the evaluation of initial evidence of the effect of rTMS.

    Time frame: Measured one time at day, at the days: 2, 13, 14, and 25.

  3. Event-related desynchronization (ERD)

    Electroencephalography (EEG) will be recorded during a cued motor task. This data will be used to calculate event-related de-synchronization, defined as the difference in signal power in the miu (8-12 Hz) and beta bands (13-30 Hz) between a baseline period prior to the cue and a post-cue period. Changes in ERD will be evaluated with permutation-based statistics.

    Time frame: Measured one time per day, at the days: 2, 13, 14, and 25.

Secondary outcomes

  1. Brain-Computer Interface accuracy

    Ratio of correct trials over the total number of trials, as a proxy of performance during brain-computer interface based training. BCI accuracy will be evaluated with a mixed-effects model. mixed-effects model. The model will consider the Patient, Period, Treatment (stimulation type) and Session number. The Period\*Treatment interaction will be verified to detect carry-over effects. The investigators expect to observe a main effect of Treatment and Session number.

    Time frame: Measured one time per day, at days 3-12 and days 15-24.

  2. Task-related functional Magnetic Resonance Imaging (t-fMRI)

    fMRI will be acquired during a motor task. The fMRI acquired during the task will be used to evaluate blood-oxygen-level-dependent (BOLD) signal changes after the active stimulation over the motor areas: premotor cortex (PMC), motor cortex (M1), supplementary motor area (SMA), cerebellum and basal ganglia; and this change will be compared with the change after placebo stimulation. In addition, the investigators will explore whether changes in BOLD signal in areas involved in BCI training can be observed after active stimulation, reflecting a potential enhancement of BCI effects. Changes in fMRI will be evaluated with a mixed-effects model in a whole-brain analysis.

    Time frame: Measured one time per day, at the days 2, 13, 14, and 25.

  3. Jebsen-Taylor Hand Function Test

    Clinical assessment of hand function that consists of 7 tasks: staking checkers, feeding, manipulating and lifting objects, writing, and page-turning. The sums of values recorded before and after the stimulation periods will be fed into an unpaired sample t-test to evaluate carryover effects whereas the differences observed between recordings before and after the stimulation will be fed into an unpaired sample t-test for the evaluation of initial evidence of the effect of rTMS.

    Time frame: Measured one time per day, at the days 2, 13, 14, and 25.

  4. Diffusion-based tractography

    Evaluation of fractional anisotropy (FA) as a proxy of white matter changes. Diffusion-weighted images will be used to used to calculate FA. FA reflects the deviation of random diffusion of water molecules in a voxel. Analysis of effects in diffusion will be carried out at the whole brain level and using contrast weights in a flexible factorial design with multiple groups of subjects.

    Time frame: Measured one time per day, at the days 2, 13, 14, and 25.

  5. Movement-related cortical potential amplitude

    Electroencephalography (EEG) will be recorded during a cued-motor task. The EEG data will be align according to the onset of the cue and averaged across trials at each time point to obtain the movement related cortical potential curves. Peak amplitudes will be compared before and after the 10 sessions of active stimulation and before and after the 10 sessions of placebo stimulation using permutation based statistics.

    Time frame: Measured one time per day, at the days 2, 13, 14, and 25.

  6. Resting-state functional Magnetic Resonance Imaging (rs-fMRI)

    In addition, the fMRI during rest will be used to analyze the connectivity between motor-related. Changes in connectivity will be explored and measured by calculation of global correlation, local correlation, amplitude low-frequency fluctuations, intrinsic connectivity and fractional amplitude low-frequency fluctuations. In addition, a seed-based analysis will be performed to check for changes in connectivity between the area of stimulation and other motor areas: M1, SMA, cerebellum and basal ganglia.

    Time frame: Measured one time per day, at the days 2, 13, 14, and 25.

  7. Voxel-based morphometry

    Voxel-based morphometry is a proxy of gray matter concentration changes based on T1-weighted MRI. This will be evaluated in response to active and placebo stimulation. A flexible factorial design will address potential changes in grey matter after the stimulation. The investigators hypothesize that changes in gray matter will be observed for the stimulated region and functionally connected areas as M1, contralateral PMC, SMA, cerebellum and basal ganglia.

    Time frame: Measured one time per day, at the days 2, 13, 14, and 25.

  8. Brain-derived neurotrophic factor (BDNF) in serum

    Serum BDNF is proposed as a marker of plasticity mechanisms. Previous studies suggest that BDNF can be modulated by multiple-session rTMS protocols. However, no study has explored changes in BDNF after excitatory rTMS protocols in stroke participants. The investigators expect a higher change in BDNF levels after active stimulation in comparison with after placebo.

    Time frame: Measured twice per day, at the days 3, 12, 15 and 24. The first measure occurs before the intervention and the second measure after the intervention.

Other outcomes

  1. Adherence

    Number of missed sessions per participant

    Time frame: Through study completion, for 25 days.

  2. Upper extremity motor activity log (UE-MAL)

    The UE-MAL is a questionnaire that inspects how much and how well the participant uses their paretic arm during activities of daily living. Participants are asked standardized questions about how often they use their more-affected arm for different activities (Amount Scale or AS) and the perceived quality of their movements when executing such tasks (How Well Scale or HW). The evaluations are done on a scale from 0 to 5. 0 represents non-use and 5 is use equal to the non- paretic hand. The scores' explanations are printed on separate sheets of paper and are placed in front of the participant during the test administration. The sums of values recorded before and after the stimulation periods will be fed into an unpaired sample t-test to evaluate carryover effects whereas the differences observed between recordings before and after the stimulation will be fed into an unpaired sample t-test for the evaluation of initial evidence of the effect of rTMS.

    Time frame: Measured one time per day, at days 2, 13, 14, and 25.

  3. Withdrawal rate

    The proportion of participants that drop out.

    Time frame: Through study completion, for 25 days.

  4. Last item of the stroke impact scale (SIS)

    The last item of the SIS will be used to ask participants to rank of their expected improvement due to the intervention from 0 to 100. This assessment will be used also after stimulation to assess the perceived improvement. The sums of values recorded before and after the stimulation periods will be fed into an unpaired sample t-test to evaluate carryover effects whereas the differences observed between recordings before and after the stimulation will be fed into an unpaired sample t-test for the evaluation of initial evidence of the effect of rTMS.

    Time frame: Measured once per day, at days 2, 13, 14, and 25.

  5. Micro fractional anisotropy (micro-FA)

    Micro-FA is a proxy of white matter integrity that in contrast with FA can resolve ambiguities caused by crossing fibers. Micro-FA values will be obtained by acquiring diffusion-weighted images with a free waveform encoding pulse sequence. The micro-FA will be evaluated in the area of stimulation and areas that show changes in FA, in order to further characterize micro-structural arrangements elicited by the brain stimulation. A second-order cumulative model will be implemented for analysis.

    Time frame: Measured once per day, at days 2, 13, 14, and 25.

  6. Glial fibrillary acidic protein (GFAP)

    GFAP will be explored as it is proposed to change with plasticity due to the transient swelling of astrocytes during structural neuronal plasticity. The investigators expect a higher change in GFAP levels after active stimulation in comparison with after placebo.

    Time frame: Measured twice per day, at the days 3, 12, 15 and 24. The first measure occurs before the intervention and the second measure after the intervention.

  7. Neurofilaments (light chain)

    Neurofilament light chains in blood will be inspected as they have been proposed as a marker of recovery after stroke. The investigators expect a higher change in Neurofilaments levels after active stimulation in comparison with after placebo.

    Time frame: Measured twice per day, at the days 3, 12, 15 and 24. The first measure occurs before the intervention and the second measure after the intervention.

  8. Beta-synuclein

    Beta-synuclein will be explored because it has been proposed as a marker of synaptic alterations. The investigators expect a higher change in Beta-synuclein levels after active stimulation in comparison with after placebo.

    Time frame: Measured twice per day, at the days 3, 12, 15 and 24. The first measure occurs before the intervention and the second measure after the intervention.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tang Z, Han K, Wang R, Zhang Y, Zhang H. Excitatory Repetitive Transcranial Magnetic Stimulation Over the Ipsilesional Hemisphere for Upper Limb Motor Function After Stroke: A Systematic Review and Meta-Analysis. Front Neurol. 2022 Jun 20;13:918597. doi: 10.3389/fneur.2022.918597. eCollection 2022. PubMed 35795793 ↗
  • Peng Y, Wang J, Liu Z, Zhong L, Wen X, Wang P, Gong X, Liu H. The Application of Brain-Computer Interface in Upper Limb Dysfunction After Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Hum Neurosci. 2022 Mar 29;16:798883. doi: 10.3389/fnhum.2022.798883. eCollection 2022. PubMed 35422693 ↗

Related links

Individual participant data

Plan to share: Yes — Data sharing will require approval by the local ethics committee (EC) of the researcher requesting the data along with public registration of the study. Data sharing will also be subject to compliance with the European Union General Data Protection Regulation.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: After the end of the study and for 10 years

Access criteria: The purpose for requesting the data and planned analysis must comply with the General Data Protection Regulation as well as Medical device regulation of the European Union.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Sep 2026, 34 months later.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 34 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Nov 3, 2023
StartEst.
Nov 8, 2023
Primary completionEst.
Sep 19, 2026
CompletionEst.
Sep 19, 2027
Last update
Nov 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06116942
Lead sponsor
Max Planck Institute for Human Cognitive and Brain Sciences
Collaborators
University of Halle Medical Faculty
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Nov 8, 2023 (estimated)
Primary completion
Sep 19, 2026 (estimated)
Completion
Sep 19, 2027 (estimated)
Last update
Nov 9, 2023

Study contacts

Aimee Arely Flores Sandoval, MsC
Contact
flores@cbs.mpg.de
+49 341 9940 ext. 2256
Arno Villringer, MD PhD
Contact
villringer@cbs.mpg.de
+49 341 9940 ext. 2220
Aimee Flores-Sandoval, MsC
study chair · Charité Universitätmedizin Berlin and Max Planck Institute for Human Cognitive and Brain Sciences
Arno Villringer, MD PhD
study director · Max Planck Institute for Human Cognitive and Brain Sciences
Bernhard Sehm, PD. med.
principal investigator · Max Planck Institute for Human Cognitive and Brain Sciences and Halle University
Vadim Nikulin, PhD.
principal investigator · Max Planck Institute for Human Cognitive and Brain Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion